is our our pembrolizumab, developing COMXXX on treatment axis drug morning have and cancer transform everyone, Thank to the effective efficiently of to On COMXXX, no who we Compugen, and second the DNAM options pathways goal evaluate PD-X. our good chemotherapy-free to novel drugs. target free by prompt, this afternoon, differentiated you, potential benefit and clinical XXXX of and of blocking were treatment TIGIT patients executing of first-in-class triple update. Yvonne. combination cancer At PVRIG, the quarter welcome our approach and immunotherapy Good discovering
this data excited positive and potential ARCUS/Gilead. a approach and interest Roche and to were the treating year, our as ASCO At axis presented we in the including others, the the momentum industry in by AstraZeneca, by community data cancer, see and of scientific own reflected DNAM-X targeting novel
presented treatment. date treat lenvatinib had patients Looking in at failed prior stable with those the have to triple our was we endometrial standard and cancer, including to microsatellite cancer with in patients, demonstrated how enthusiasm totality among pembro regarding approach there of combination care, data the spoke responses with of who we
other no were there patients, options. these For treatment
to treat In overall rate cancer antitumor responses resistant is reported stable a inhibitor including with patients. naïve combinations platinum expect immune hard patients, experienced lung durable and and response tumors, cell based were patients an of activity data activation XX%. COMXXX we ovarian endometrial control The by in the other microsatellite checkpoint consistent non-small would alone. than what disease XX% better showed This an anti-PD-X for one we rate of supported cancer, colorectal cancer for with and
expression patients treatment the for a with levels, of to of mechanism option safety COMXXX mediated to immunotherapy, Reflecting have anti-PD-X PD-LX based are favorable spectrum refractory, to our responsive to potential the COMXXX to how pointing of a who treatment combinations suggests patients typically in data standard on of not our totality a patients treat action. profile across in the that potential date, the offer data including care,
is continuing to important focus platinum in ovarian colorectal discovery, which resistant is indications, cancer forward. our cancer, in expanding and X MSS setting in immediate on efficiently development while path Our biomarker data our invest
However, part these maybe than indications. of as much of DNAM-X axis that we COMXXX broader potential X the believe therapeutic the
clinical mentioned exposed anti-tumor its in As and profile to at on and presented to bispecific and antibody AstraZeneca from safety previously derived activity immunotherapy. earlier, ASCO pharmacokinetic checkpoint patients not PD-X/TIGIT results showing rilvegostomig, inhibitors usually COMXXX, responsive establishing a
this AstraZeneca Phase in continues non-small in announced development hepatobiliary plans a multiple previously lung inhibitor and cancer cancer year. to patients or X cell rilvegostomig to trial a studies X advance initiate checkpoint trial and Phase in a including X naïve trial Phase
Fc are antitumor an inactive We with like designed know and to which COMXXX, to have was anti-TIGITs reduced engineered anti-TIGIT the same effector enhance activity. with rilvegostomig that not is domain Fc an all function
Another inactive in function this anti-TIGIT. ARCUS is camp Fc of program or effect reduced
the ARCUS/Gilead has ASCO, with showed versus blocking with alone shown what Fc-active profile safety potential PD-X survival to continued At improvement been anti-TIGIT. to better progression-free date in
doubling Blocking great ASCO session Another standard at randomized line cancer rate standard third Roche a top TIGIT progression-free greater showing in the that’s these trial cancer trial of overall gained Roche hepatocellular the results. adding TIGIT and liver is care. a data. interest first X-time and an was of anti-TIGIT in resulted on to benefit This of initiated on care X a response Phase based of the has survival
in as We presentations another treatment. hard which for potential indication a PVRIG treat discussant that serve Roche fit hepatocellular may COMXXX the the cancer. were This significance pleased of to highlighted of blockade adding is
see PVRIG last in cancer. great PD-X with diseases in SITC on awareness role was unexpected which presented showing responses from to data PVRIG stable Overman to ASCO another is at of approaches Dr. by colorectal of was novel by also combination cancer PVRIG inhibitors, presenter blocking microsatellite increased called the in immunotherapy. role session our year, led Anderson an MD out Mike checkpoint that in to intrigued important in It The like
Compugen’s all approach highlight differentiated how we to important is among out It players. stand and the
said have enough PVRIG and be we that needed. Firstly, be always not blocking may may TIGIT that
in discovery the is belief as of to support target have it. drug context to data being conducted consistently unlocking extensive rollout axis multiple we its across need the block a the reinforced indications. and PVRIG the as we function DNAM of our clinical of This Our new test biological research, the effect
anti-TIGIT. And clinical Fc-effective data approach either finally, immune have. Fc suggests the our TIGIT have our with COMXXX matter PVRIG, and better DNAM a function as domain be with Secondly, to inactive COMXXX, Fc best-in-class unique we a hypothesis. believe not X may axis the and blocking PVRIG today potentially were may to of free the wholly-owned combination The in X PD-X, we antibody support or reduced checkpoint leaders and or initial data programs design TIGIT triple TIGIT chemotherapy it we reduced available have of that
we to half first additional ASCO, in progress I the the refer to have like made Along with a successful very of year. would
be patient completed we enrollment advancing the proof-of-concept the the We’re study can MSS we study, track is enrollment in additional ovarian follow-on catch studies. a in Enrollment year. cancer with our planned slower on of resistant planned but end up is by on than in sites. believe Enrollment platinum X CRC of the to activation
the indications. lead path patients reminder, to of of these help to on most studies the provides believe to this We de-risk assets data, respond. our and a more our these strategy identify to the understand two forward efficiently work contribution us is COMXXX fastest likely way obtain development components to COMXXX and the better As goal build potentially set extensive biomarker and that in
CIMT anti-IL-XX resistance. potential there and protein binding we innovative Europe’s of this Conference. in antibody data addressing year, of its development a Annual first-in-class our We to excitement this around immunotherapy approach on potential May Conference, COMXXX at our presented leading is COMXXX In Immunology believe the program
first a the Office a our the discovery favorable in progress half the cancer. we is PVRIG’s Patent delighted European role European the patent. immune uphold claims for ruling on our Patent PVRIG to of broad the were innovation, with in Office the for target This a Finally, of checkpoint drug the win and as novel of XXXX, of ruling
of discovery that strategy broad a target excels harness of discovery takes targets, we the As that patent company novel new drug in our advantage capability. the
moving should year. over you the second of us Now, see to on from half expect the to what
final the conference at initial XXXX. the our proof-of-concept we data plan report medical by a First, to studies of in from year findings end and ongoing
Second, we’re from all as well the COMXXX studies our data the and ESMO-IO by platinum last at ovarian of data new follow-up presented from initial long-term our program translational end expecting as additional biomarker year. year, patient to preclinical present resistant and cancer
patients to also available plan from with this into present inhibitors COMXXX XX which We enrolled nivolumab. and treatments, immune These standard checkpoint were exhausted new HERX ER/PR ADCs. treated all were and had data Patients of of could and patients cancer their breast heavily pretreated the and status. regardless include study metastatic cohort
into touch will Alberto, to over finances, details. Alberto handing then Before I the briefly and on go our will
reach and which XXXX, at sufficient We planned have is assets least operations an all our of and to cash the COMXXX expected lead to through runway believe potentially de-risk support we end milestones COMXXX.
it used funding, future worth noting assets combination believe funding COMXXX profile ideal combine non-dilutive make is settings. earlier to lead and our this our of we to our the them in of COMXXX priority. the front, and pipeline is terms is trend immunotherapy earlier, and In assets of in treat that On treatment candidates be
a we’re excitement increasing that is have pathway optimal in biology cytokine differentiated IL-XX cancer. we modulation approach potentially in there And with immunooncology. for to Additionally, this the harness use happy COMXXX, around potential treating of
partnership our future milestone payments. become eligible we for through may with Finally, AstraZeneca,
Alberto hand for with update. to And that, I over will the financial
